2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117634
    WS009B 136286-50-5 98%
    WS009B is a selective endothelin receptor antagonist (ET-1: IC50=0.67 μM; ET-2: IC50=0.8 μM). WS009B can be used in the study of cardiovascular diseases.
    WS009B
  • HY-117644
    L-749329 159590-37-1 98%
    L-749329 ((Rac)-L-754142) is an ETA and ETB receptor antagonist, with Kis of 0.062 nM and 2.25 nM for ETA and ETB respectively. L-749329 inhibits ET-1-stimulated signaling.
    L-749329
  • HY-117798
    LY 806303 149725-15-5 98%
    LY 806303 is a potent and selective inhibitor of human α-thrombin. LY 806303 specifically acylates Ser-205 within the catalytic triad of α-thrombin on the heavy chain and a key site involved in the enzymatic activity of thrombin. The mechanism of action of LY 806303 as an enzyme inhibitor is through the specific acylation of this catalytic serine residue.
    LY 806303
  • HY-117805
    UR-7247 177847-28-8 98%
    UR-7247 is a potent and orally active angiotensin II AT1 receptor antagonist. UR-7247 decreases arterial pressure and increases renal blood flow.
    UR-7247
  • HY-117858
    CL-329167 143945-39-5 98%
    CL-329167 (compound 12) is an orally active and competitive angiotensin II receptor antagonist (IC50=6 nM). CL-329167 can be used in the research of hypertension.
    CL-329167
  • HY-117913
    ES-8891 129445-88-1 98%
    ES-8891 is a renin inhibitor. Oral administration of ES-8891 to normotensive sodium-depleted macaques for one week significantly reduced plasma renin activity, immunoreactive renin concentrations, and plasma angiotensin I concentrations, while mean blood pressure decreased significantly, without significant changes in heart rate. ES-8891 regulates blood pressure by inhibiting plasma renin levels and renal renin synthesis.
    ES-8891
  • HY-117961
    Candoxatrilat 123122-54-3 98%
    Candoxatrilat (UK 73967) is an orally active inhibitor of neutral endopeptidase. By elevating the levels of atrial natriuretic peptides, Candoxatrilat exerts its diuretic and natriuretic effects. Candoxatrilat is utilized in the research of heart failure.
    Candoxatrilat
  • HY-118164
    Ro 31-8472 144284-57-1 98%
    Ro 31-8472 is a Cilazapril (HY-A0043) derivative. Ro 31-8472 is an angiotensin-converting enzyme (ACE) inhibitor.
    Ro 31-8472
  • HY-118232
    VUF8504 112575-50-5 98%
    VUF-8504 is a potent and selective adenosine A3 receptor antagonist with Ki value of 0.017, 14 nM for human A3, A1, respectively.
    VUF8504
  • HY-118236
    (S)-AZD 6482 1173900-37-2 98%
    (S)-AZD6482 ((S)-KIN-193) is a highly effective and selective ATP-competitive inhibitor of PI3Kβ, exhibiting an IC(50) of 0.01 μM, and it can reduce insulin-induced glucose uptake by human adipocytes in vitro with an IC(50) of 4.4 μM.
    (S)-AZD 6482
  • HY-118264
    MDL-100240 142695-08-7 98%
    MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.
    MDL-100240
  • HY-118268
    RG 6866 120602-97-3 98%
    RG 6866 is a 5-lipoxygenase (5-LOX) inhibitor with the potential to inhibit coronary artery constriction and negative cardiac inotropic effects in cardiac inflammatory states. When the heart is stimulated by antigens, RG 6866 can block the antigen-induced reduction in coronary flow in the heart.
    RG 6866
  • HY-118317
    Zacopride 90182-92-6 98%
    Zacopride is an orally active 5-HT3 receptor (Ki of 0.38 nM) antagonist and 5-HT4 receptor (Ki of 373 nM) agonist. Zacopride exhibits multiple activities, such as regulating gastrointestinal motility, affecting cardiac function, and exerting anxiolytic and antiemetic effects. Zacopride is currently mainly used in the research of gastrointestinal diseases, cardiovascular diseases, and psychiatric diseases such as anxiety.
    Zacopride
  • HY-118492
    Riodipine 71653-63-9 98%
    Riodipine (PP-1466) is a vasodilator. Riodipine can be used for the research of antihypertensive.
    Riodipine
  • HY-118518
    Ronipamil 85247-77-4 98%
    Ronipamil is a calcium ion antagonist. Ronipamil increases the specific binding and internalization of human 125I-LDL in human skin fibroblasts (HSF) and the human hepatoma cell line Hep G2.
    Ronipamil
  • HY-118642
    D-Ribose-L-cysteine 232617-15-1 98%
    D-Ribose-L-cysteine ​​is an orally active cysteine ​​analog. D-Ribose-L-cysteine ​​improves cellular antioxidant capacity by enhancing intracellular glutathione (GSH) biosynthesis. In addition, D-Ribose-L-cysteine ​​has a memory-enhancing effect and can reverse Scopolamine (HY-N0296)-induced memory impairment by inhibiting oxidative stress and acetylcholinesterase (AChE) activity. D-Ribose-L-cysteine ​​can be used in the study of neurodegenerative and cardiovascular diseases.
    D-Ribose-L-cysteine
  • HY-118670
    16(S)-Iloprost 74843-14-4 98%
    16(S)-Iloprost is a stereoisomer of Iloprost. 16(S)-Iloprost inhibited platelet aggregation with IC50 value of 3.5 nM, and balanced binding with platelet membrane receptors Kd value of 13.4 nM.
    16(S)-Iloprost
  • HY-118736
    Ganodermic acid S 112430-63-4 98%
    Ganodermic acid S is an oxygenated triterpenoid, that can be isolated from the Chinese medicinal fungus Ganoderma lucidum (Fr.) Karst (Polyporaceae). Ganodermic acid S exerts a concentration dependent inhibition on the response of human gel-filtered platelets (GFP) to U-46619 (HY-108566), a thromboxane (TX) A2 mimetic.
    Ganodermic acid S
  • HY-118765
    Ro 23-3423 110996-51-5 98%
    Ro 23-3423 is a thromboxane synthase inhibitor with an IC50 value of 0.33 μM for human platelet microsomal thromboxane synthase. Ro 23-3423 increases plasma levels of PGF and PGE2 in a dose-dependent manner, accompanied by a decrease in mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 can be used in the study of general anesthesia.
    Ro 23-3423
  • HY-118895
    L-641953 89825-69-4 98%
    L-641953 is an orally active, selective TXA/PG-END receptor (thromboxane-prostaglandin endoperoxide receptor) antagonist. L-641953 significantly inhibits arachidonic acid-induced bronchoconstriction. L-641953 may be used in cardiovascular disease research.
    L-641953
Cat. No. Product Name / Synonyms Application Reactivity